At the American Urological Association's annual meeting (AUA24) in San Antonio, CG Oncology presented updated Phase 3 study results for its bladder cancer drug, cretostimogene. The study, known as BOND-003, showed that the drug drove non-muscle invasive bladder cancer into remission in 75% of the participants. This presentation marks the first significant test of the drug since CG Oncology's IPO in January. The results were highlighted by Dr. Mark Tyson at the Stars at Night Ballroom, followed by an opportunity for attendees to meet with the CG Oncology Medical Team.
New data is out today about @cgoncology's drug cretostimogene, the first stress test since its January IPO. Their experimental treatment drove non-muscle invasive bladder cancer into remission in 75% of people who received it in a Phase 3 study: https://t.co/yojctPteYo
CG follows big IPO with new results for bladder cancer drug https://t.co/CwNmy96ywQ $CGON by @gwendolynawu
CG follows big IPO with new results for bladder cancer drug https://t.co/hRm4Wvtdxn by @gwendolynawu $CGON
$CGON catalyst coming up at the #AUA24 in San Antonio with @MarkTysonMD in ~1.5 hours from now at 10:23am CDT. Note this is Phase 3 study results of cretostimogene from BOND-003 of @CGOncology #cancer #BladderCancerAwarenessMonth #bladdercancer https://t.co/ARlNlYnP2j
We’re at #AUA24, where we’re presenting our latest #ProstateCancer research and connecting with the #urology community, who shares our mission of helping to change patient lives. https://t.co/qGqbXF02VT
👋 Hello #SanAntonio! We're excited for #AUA24! Join @MarkTysonMD today, 5/3 at 10:23 am CDT for updated BOND-003: Phase 3 study results of cretostimogene in the Stars at Night Ballroom. Afterwards, meet the @CGOncology Medical Team at booth #100. ➡️ https://t.co/cOADzltuj9 https://t.co/dBdgdy7ax3